Pembrolizumab and Lenvatinib for Recurrent Endometrial Cancer
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This trial tests a combination of two drugs (pembrolizumab and lenvatinib) for endometrial cancer that has come back after initial treatment with chemotherapy and immunotherapy. The study focuses on a specific type of cancer based on genetic testing and may help patients whose cancer didn't respond to standard first-line treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Endometrial cancer that has returned after failing chemotherapy plus immunotherapy as your first treatment
- Specific genetic profile (mismatch repair proficient) confirmed by lab testing
- Measurable cancer visible on imaging scans
- Completed genetic sequencing (next-generation sequencing) of your tumor
- Good enough overall health to tolerate the trial drugs (ECOG performance status 0–3)
- Blood work showing adequate liver, kidney, and bone marrow function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests whether taking two oral medications (letrozole and abemaciclib) after standard chemotherapy can help keep advanced or recurrent endometrial cancer from coming back. It is for people whose cancer is estrogen receptor-positive and has certain favorable genetic features.
This study tests a combination of two drugs (lenvatinib and pembrolizumab) plus focused radiation to the pelvis for a specific type of endometrial cancer that has returned or cannot be surgically removed. The goal is to see if this treatment is safe and effective for tumors that are pMMR and limited to the pelvic area.
This study tests a combination of two drugs, pembrolizumab (an immunotherapy) and lenvatinib (a targeted therapy), for people with cervical cancer that has come back or spread. The goal is to see if this drug combination can shrink tumors or slow the cancer's growth.
This Phase 3 study tests whether adding a repurposed drug to Keytruda and Lenvima (Len+Pem) helps people with advanced or recurrent endometrial cancer live longer and feel safer. It is designed for tumors that do not have certain immune-system markers (not MSI-H or dMMR).
This Phase 2 trial tests whether a repurposed drug can be safely added to Keytruda and Lenvima for women with advanced or recurrent endometrial cancer. It’s meant to help people who can’t have curative surgery or radiation after prior chemotherapy.
This Phase 2 trial studies whether pembrolizumab and lenvatinib can improve outcomes in people with advanced cervical cancer that has grown or stopped responding to earlier treatments. It may help by boosting the immune system and slowing cancer growth.
Hear when a new Recurrent Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.